Lanthanum Carbonate Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 500 mg 750 mg 1,000 mg
Reference Brands: Fosrenol (US & EU)
Category:
Nephrology
Lanthanum Carbonate is a phosphate binder used to manage hyperphosphatemia in chronic kidney disease (CKD) patients, especially those on dialysis. It helps reduce serum phosphate levels, preventing complications like vascular calcification and bone disease in end-stage renal disease (ESRD) patients.
Lanthanum Carbonate is available in Tablet
and strengths such as 500 mg 750 mg 1,000 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Lanthanum Carbonate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Lanthanum Carbonate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Lanthanum Carbonate is a phosphate binder used to treat hyperphosphatemia in chronic kidney disease (CKD) patients, particularly those on dialysis. By binding to dietary phosphate, it reduces its absorption and helps control serum phosphate levels, preventing complications such as vascular calcification and bone disease in end-stage renal disease (ESRD) patients. Available for B2B distribution in the US and EU, Lanthanum Carbonate is essential for managing phosphate balance in dialysis patients. Its role in improving bone health and minimizing secondary hyperparathyroidism makes it a key therapeutic solution in nephrology.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing